Cooper Companies (COO) – Analysts’ Recent Ratings Changes

Several analysts have recently updated their ratings and price targets for Cooper Companies (NYSE: COO):

  • 9/27/2018 – Cooper Companies was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 9/24/2018 – Cooper Companies was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Cooper Companies’ portfolio of daily silicone hydrogel lenses makes it one of the stalwarts in the soft contact lens market. The company continues to gain from the PARAGARD acquisition which has consistently driven the CooperSurgical segment. CooperVision has also seen strong growth with solid performance in the United States, EMEA and Asia Pacific. A significant expansion of the gross and operating margins buoy optimism. Management is optimistic about the clarity, MyDay and Biofinity suite of products. Cooper Companies’ strong fertility portfolio and fiscal 2018 guidance are encouraging. On the flipside, sales of the company’s Avaira lenses declined significantly in recent times. Foreign exchange volatility persists as well. A competitive contact lens industry adds to the woes. The stock is overvalued at the moment. Cooper Companies underperformed its industry in a year's time.”
  • 9/21/2018 – Cooper Companies had its price target raised by analysts at Raymond James from $270.00 to $300.00. They now have an “outperform” rating on the stock.
  • 9/12/2018 – Cooper Companies was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Cooper companies’ portfolio of daily silicone hydrogel lenses makes it one of the stalwarts in the soft contact lens market. The company continues to gain from the PARAGARD acquisition which has consistently driven its CooperSurgical segment. CooperVision also saw strong growth with solid performance in the United States, EMEA and Asia Pacific. A significant expansion of the gross and operating margins buoy optimism. Management is optimistic about the clarity, MyDay and Biofinity suite of products. Cooper’s strong fertility portfolio and fiscal 2018 guidance are encouraging. Sales of Avaira declined significantly in the last-reported quarter. Foreign exchange volatility persists as well. Series of acquisitions pose significant integration risks. A competitive contact lens industry adds to the woes. The stock is overvalued at the moment. Cooper Companies underperformed the industry in a year’s time.”
  • 9/3/2018 – Cooper Companies was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Cooper exited fiscal third quarter on a tepid note. Sales of Avaira declined in the quarter. Foreign exchange volatility persists as well. Series of acquisitions pose significant integration risks. A competitive industry adds to the woes. The stock is overvalued at the moment. Cooper underperformed the industry in a year’s time. However, the company continues to gain from the PARAGARD acquisition which has consistently driven CooperSurgical. CooperVision also saw a strong quarter with solid performance in the United States, EMEA and Asia Pacific. A significant expansion of the gross and operating margins buoy optimism. Management is optimistic about the clarity, MyDay and Biofinity suite of products. The company’s portfolio of daily silicone hydrogel lenses makes it one of the stalwarts in the soft contact lens market. Cooper’s strong fertility portfolio and fiscal 2018 guidance are encouraging.”
  • 8/31/2018 – Cooper Companies had its price target raised by analysts at BMO Capital Markets from $280.00 to $285.00. They now have an “outperform” rating on the stock.
  • 8/31/2018 – Cooper Companies was given a new $270.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “hold” rating on the stock.
  • 8/16/2018 – Cooper Companies was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Cooper Companies currently rides on strong performance by its core CooperVision unit. Growth in the segment can be attributed to significant year-over-year increase in single-use sphere lens revenues. Geographically as well, the company has registered gains. The acquisition of PARAGARD has driven CooperSurgical revenues. Management is optimistic about the recently-completed acquisition of LifeGlobal which is expected to enhance Cooper Companies’ fertility business. Further, continued improvement in gross and operating margin is promising. On the flip side, Cooper’s long-term debt has increased significantly, which raises concern. Foreign exchange volatility continues to persist. Moreover, a series of acquisitions pose significant integration risks. Stiff competition in the niche space also adds to the woes. The stock looks overvalued at the moment. The company underperformed the industry in a year’s time.”
  • 8/8/2018 – Cooper Companies was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $288.00 price target on the stock. According to Zacks, “Cooper Companies currently rides on strong performance by its core CooperVision unit. Growth in the segment can be attributed to significant year-over-year increase in single-use sphere lens revenues. Geographically as well, the company has registered gains. The acquisition of PARAGARD has driven CooperSurgical revenues. Management is optimistic about the recently-completed acquisition of LifeGlobal which is expected to enhance Cooper Companies’ fertility business. Further, continued improvement in gross and operating margin is promising. On the flip side, Cooper’s long-term debt has increased significantly, which raises concern. Foreign exchange volatility continues to persist. Moreover, a series of acquisitions pose significant integration risks. Stiff competition in the niche space also adds to the woes. The stock looks overvalued at the moment. The company underperformed the industry in a year’s time.”

Cooper Companies stock opened at $274.50 on Thursday. Cooper Companies Inc has a 12 month low of $216.47 and a 12 month high of $276.31. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.58 and a quick ratio of 1.54. The company has a market cap of $13.41 billion, a PE ratio of 28.30, a P/E/G ratio of 2.18 and a beta of 0.67.

Cooper Companies (NYSE:COO) last released its quarterly earnings results on Thursday, August 30th. The medical device company reported $3.00 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $3.07 by ($0.07). The company had revenue of $660.00 million for the quarter, compared to analysts’ expectations of $653.44 million. Cooper Companies had a return on equity of 17.53% and a net margin of 5.23%. sell-side analysts anticipate that Cooper Companies Inc will post 11.62 EPS for the current fiscal year.

In other Cooper Companies news, SVP Agostino Ricupati sold 1,575 shares of the stock in a transaction on Thursday, September 6th. The stock was sold at an average price of $261.56, for a total value of $411,957.00. Following the completion of the transaction, the senior vice president now owns 1,897 shares in the company, valued at $496,179.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Daniel G. Mcbride sold 2,147 shares of the stock in a transaction on Friday, June 29th. The stock was sold at an average price of $235.13, for a total value of $504,824.11. Following the completion of the transaction, the chief operating officer now owns 28,395 shares of the company’s stock, valued at approximately $6,676,516.35. The disclosure for this sale can be found here. Insiders sold 87,725 shares of company stock valued at $22,318,098 in the last quarter. 1.60% of the stock is currently owned by company insiders.

A number of large investors have recently added to or reduced their stakes in COO. BlackRock Inc. increased its position in shares of Cooper Companies by 0.9% in the first quarter. BlackRock Inc. now owns 3,647,931 shares of the medical device company’s stock valued at $834,681,000 after buying an additional 31,592 shares in the last quarter. IFP Advisors Inc increased its position in shares of Cooper Companies by 94.0% in the first quarter. IFP Advisors Inc now owns 912 shares of the medical device company’s stock valued at $209,000 after buying an additional 442 shares in the last quarter. Toronto Dominion Bank increased its position in shares of Cooper Companies by 25.1% in the first quarter. Toronto Dominion Bank now owns 26,420 shares of the medical device company’s stock valued at $6,044,000 after buying an additional 5,303 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Cooper Companies by 39.6% in the first quarter. JPMorgan Chase & Co. now owns 265,364 shares of the medical device company’s stock valued at $60,716,000 after buying an additional 75,209 shares in the last quarter. Finally, First Republic Investment Management Inc. increased its position in shares of Cooper Companies by 2.0% in the first quarter. First Republic Investment Management Inc. now owns 21,614 shares of the medical device company’s stock valued at $4,946,000 after buying an additional 434 shares in the last quarter. Hedge funds and other institutional investors own 97.06% of the company’s stock.

The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.

Featured Article: Find a Trading Strategy That Works

Receive News & Ratings for Cooper Companies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply